The use of leukocytes' secretome to individually target biological therapy in autoimmune arthritis: a case report.

ABSTRACT:

Background

Biological agents have allowed remarkable improvement in controlling autoimmune arthropathies, although none of the numerous biologics readily available represent a universal treatment standard. Moreover, classical and genetic predictors are currently unsatisfactory to predict individual response to a biologic, and the best treatment selection is still based on a trial-and-error approach. Here, we report a clinical case demonstrating the usefulness of examining the leukocytes' secretome of patients. We set up and standardized a protocol that examines a patient's immune responses to establish the secretome of the blood mononuclear leukocytes and personalize the biotherapy.

Case presentation

A 24-year-old woman was diagnosed with active early rheumatoid arthritis. T

SUBMITTER: Poubelle PE 

PROVIDER: S-EPMC6548783 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature